REFERENCES
- Jensen CE, Tuck SM, Agnew JE, High prevalence of low bone mass in thalassaemia major. Br J Haematol. 1998; 103(4):911–915.
- Filosa A, Di Maio S, Vocca S, Longitudinal monitoring of bone mineral density in thalassaemic patients: genetic structure and osteoporosis. Acta Paediatr. 1997; 86(4):342–346.
- Angastiniotis M, Pavlides N, Aristidou K, Bone pain in thalassemia: assessment of DEXA and MRI findings. J Pediatr Endocrinol Metab. 1998; 11(3):779–784.
- Glastre C, Braillon P, David L. Measurement of bone mineral content of the lumbar spine by dual energy X-ray absorptiometry in normal children: correlations with growth parameters. J Clin Endocrinol Metab. 1990; 70(5):1330–1333.
- Cheng JC, Leung SS, Lee WT, Determinants of axial and peripheral bone mass in Chinese adolescents. Arch Dis Child. 1998; 78(6):524–530.
- Leung TF, Hung EC, Lam CW, Bone mineral density in children with thalassemia major: determining factors and effects of bone marrow transplantation. Bone Marrow Transplant. 2005; 36(4):331–336.
- Gaudio A, Morabito N, Xourafa A, Bisphosphonates in the treatment of thalassemia-associated osteoporosis. J Endocrinol Invest. 2008; 31(2):181–184.
- Perifanis V, Vyzantiadis T, Tziomalos K, Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with β-thalassemia. Ann Hematol. 2007; 86(1):23–30.
- Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Zoledronic acid for the treatment of osteoporosis in patients with β-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica. 2006; 91(9):1193–1202.
- Voskaridou E, Terpos E, Spina G, Pamidronate is an effective treatment for osteoporosis in patients with β-thalassaemia. Br J Haematol. 2003; 123(4):730–737.
- Johnston CC, Melton LJ III, Lindsay R, Eddy D. Clinical indications for bone mass measurement. J Bone Miner Res. 1989; 4(1):1–28.
- Gafni RI, Baron J. Overdiagnosis of osteoporosis in children due to misinterpretation of dual-energy X-ray absorptiometry (DEXA). J Pediatr. 2004; 144(2):253–257.
- Wonke B, Jensen C, Hanslip JJ, Genetic and acquired predisposing factors and treatment of osteoporosis in thalassemia major. J Pediatr Endocrinol Metab. 1998; 11(Suppl. 3):795–801.
- Rioja L, Hany Y, Garabedian M, Cournot-Witmer G. Bone disease in children with homozygous β‐thalassemia. Bone Miner. 1990; 8(1):69–86.
- Chan YL, Pang LM, Chik KW, Patterns of bone diseases in transfusion-dependent homozygous thalassemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia. Pediatr Radiol. 2002; 32(7):492–497.
- Morabito N, Lasco A, Gaudio A, Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporosis Int. 2002; 13(8):644–649.
- Gilfillan CP, Strauss BJ, Rodda CP, A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia. Calcif Tissue Int. 2006; 79(3):138–144.
- Voskaridou E, Christoulas D, Konstantinidou M, Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica. 2008; 93(10):1588–1590.
- Vogiatzi MG, Macklin EA, Fung EB, Prevalence of fractures among the thalassemia syndromes in North America. Bone. 2006; 38(4):571–575.
- Vogiatzi MG, Macklin EA, Fung EB, Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res. 2009; 24(3):543–557.